Investors
A sharp wedge before a broad platform.
Cytogent has built the Experimental Intelligence Layer for oncology R&D, delivered as Decision-as-a-Service. We are starting narrow on purpose: one resistance setting, one kind of decision, and clear gates that have to be passed before anything broader.
Why this beachhead
A proving ground, not a market claim.
Resistance after osimertinib in EGFR-mutant lung cancer is well described, varied and actively studied. That makes it a demanding test: if better experiment selection changes decisions here, the result is hard to explain away.
Compounding, by design
What should get better with each wave.
The design aim is that each wave leaves something behind: longitudinal outcomes including negatives, confirmed findings, a sharper workflow and stronger lab partnerships, each kept within its sponsor’s governance terms.
Validation aims
Six gates.
These are aims we will be measured against. None is presented here as achieved.
- GATE 1AIM
Buyer pull
Drug teams commit time and budget to a pilot question.
- GATE 2AIM
Model access
Reliable access to suitable resistant and matched parental models.
- GATE 3AIM
Matched benchmark
Loop-selected batches compared fairly with how the team would otherwise choose.
- GATE 4AIM
Prospective economic proof
Evidence, measured going forward, that better selection saves experiments or time.
- GATE 5AIM
Cross-lab reproducibility
Key signals confirmed in an independent laboratory.
- GATE 6AIM
Paid multi-wave
A sponsor pays for repeated waves because the first was worth it.
